The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.
The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.
CareFirst covers more than 3 million patients in Maryland, Washington DC, and Virginia, and is one several payors to recently issue a coverage decision for Vermillion.
The insurer will cover Metamark's urology specialized diagnostics throughout the state.
The colon cancer screening test is now covered in-network by the insurance company in Indiana, Ohio, Kentucky, Missouri, and Wisconsin.
Sequenom has secured in-network status with seven state Anthem BCBS plans to provide NIPT to both high- and average-risk pregnancies.
Exact Sciences' CEO recently discussed the added coverage on a call with analysts to discuss Exact's Q4 earnings.
The company alleges that the insurer has illegally and improperly refused to pay more than $410,000 for its colorectal cancer screening test Cologuard.
The company said the agreement will make its cancer diagnostics and genomic tests available to more than 2.6 million people.
A US health insurer announces that it will cover the whole-genome sequencing of some cancers, Modern Healthcare reports.
Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.
An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.